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Differences in Primary Care Clinicians’ Approach to
Non-small Cell Lung Cancer Patients Compared with
Breast Cancer
Timothy R. Wassenaar, MD,*† Jens C. Eickhoff, PhD,*§ Daniel R. Jarzemsky, MD,*‡
Stevens S. Smith, PhD,*† Marilyn L. Larson, MS,*† and Joan H. Schiller, MD,*†¶
Background: Lung cancer is a disease with a stigma of being
primarily self-induced. We hypothesize that this negative connota-
tion for patients and physicians could lead to differences in referral
patterns, treatment, and, ultimately, poorer outcomes compared with
patients with non–self-induced diseases. We conducted a survey
of primary care physicians to determine whether treatment and
referral patterns of breast cancer patients differed from those of lung
cancer patients.
Methods: Case scenarios were mailed to 1132 primary care physi-
cians in Wisconsin. Physicians were randomized to receive one of
four scenarios on the basis of cancer type and smoking status.
Physicians’ referral patterns, length of follow-up, and knowledge
about the benefits of chemotherapy were compared.
Results: Six hundred seventy-two physicians replied (response rate
59.4%). On the basis of the responses to the clinical scenarios,
physicians were less likely to refer patients with advanced lung
cancer than patients with advanced breast cancer (p  0.001). More
physicians knew that chemotherapy improved survival in advanced
breast cancer than in advanced lung cancer (p  0.0145). Breast
cancer patients were more likely to be referred for further therapy,
whereas lung cancer patients were often referred only for symptom
control (p  0.0092). Yet, when asked directly, physicians stated
that type of cancer was not a factor in their decisions to refer
patients. There were no statistically significant differences between
smoking and nonsmoking patients.
Conclusions: There is a difference in referral patterns and a lack of
knowledge in the primary care community regarding the benefit of
treatment of patients with lung cancer compared with breast cancer
patients.
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(J Thorac Oncol. 2007;2: 722–728)
Lung cancer causes more deaths each year than breast,colon, and prostate cancers combined.1 Because it results
from tobacco use in the majority of cases, it is associated with
a stigma of being self-induced. This stigma has been studied
extensively in the case of HIV/AIDS, with multiple studies
showing that a disease-associated stigma negatively affects
perception and treatment of the people living with the disease
as well as quality of care from physicians.2–4 Similarly, there
have been a number of studies looking at this issue of stigma
in patients with eating disorders and obesity.5,6 Nevertheless,
few studies exploring guilt, shame, and stigma have been
performed for patients with lung cancer. An Italian study has
shown that lung cancer patients felt that a stigma existed
towards them by their friends, family, and physicians who
assumed that their lung cancer had been caused by smoking,
even if they had never smoked or had quit smoking years
before their diagnosis.7 Nevertheless, it is unclear whether
this stigma affects primary care providers, which could lead
to differences in the care and treatment of these patients and,
ultimately, to poorer outcomes. Recently, lung cancer pa-
tients and advocates have become increasingly concerned
about possible disparities in treatment compared with non–
self-induced malignancies.
It is also unclear whether perceived poor survival or
ineffective treatments might play a role in treatment bias regard-
ing lung cancer. Although the outcome for advanced lung cancer
remains grave in comparison with some malignancies, multiple
studies have shown significant advances during recent years in
treatment and symptom management.8–10 This has resulted in
improved quality of life and in longer survival for these patients.
Nevertheless, a lack of knowledge in physicians was suggested
in a survey study, which showed that almost 40% of primary
physicians recommended only supportive and palliative care for
patients with advanced-stage lung cancer (stage IV), even
though multiple studies have shown that these patients can
benefit significantly from chemotherapy.11
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We hypothesized that primary care physicians approach
the treatment and referral of lung cancer patients differently
than they do patients with other malignancies, such as breast
cancer, possibly because of factors such as stigma relating to
patients’ use of tobacco, the number of lung cancer patients in
the physicians’ practice, or a lack of knowledge regarding the
advances in therapy for lung cancer.
METHODS
Participants
A cover letter and case scenarios were sent to all 1132
Wisconsin physicians who were identified as members of the
American College of Physicians–Internal Medicine and the
American Academy of Family Physicians through their re-
spective directories. The study protocol was approved by the
institutional review board at the University of Wisconsin.
Questionnaire
The questionnaires were initially developed by one of
us (J.S.) and then revised on the basis of the evaluation and
comments of the remaining authors and a small group of
medical oncologists. The surveys were then distributed a pilot
group of internal medicine physicians at the University of
Wisconsin to help gauge the effectiveness and clarity of the
survey. The questionnaires were developed with the primary
goal of evaluating how primary physicians approach the
management and referral of patients with two different ma-
lignancies—breast and lung cancer—but with the same stage
of disease. The questionnaires included patients’ scenarios
from their presentation with stage IB disease through primary
treatment, to the development of metastatic disease, and,
eventually, to end-of-life care. In addition, the cases were
further subdivided into patients with both breast and lung
cancer who did or did not use tobacco. This resulted in the
development of four different surveys, two with scenarios of
nonsmoking patients with breast and lung cancer and two
with smoking patients with breast and lung cancer. The
surveys were identical in every way, with the exception of
tumor type and smoking status. A sample version of the
questionnaire can be seen in Appendix A.
Briefly, each of the survey questionnaires consisted of
three sections. The first section contained questions about
physician demographics and basic characteristics about the
physicians, and the second section contained the clinical
scenarios. The final section of the survey asked physicians
what specific factors influenced their decision to refer patients
to a medical oncologist, including type of cancer, stage of
disease, degree of symptoms, patients’ desire, and age of the
patient; a respondent also could fill in his or her own reasons.
Study Design
A total of 1132 primary care physicians were random-
ized into four equal groups of 283 that received one of the
following questionnaires: (a) a female smoker/lung cancer
scenario, (b) a female nonsmoker/lung cancer scenario, (c) a
female smoker/breast cancer scenario, and (d) a female non-
smoker/breast cancer scenario. Physicians were surveyed
with an initial mailing in April, 2005, and then with a repeat
mailing in August 2005. The physicians had an option of
filling out and returning the paper copy of the survey, or they
could access an electronic copy of the survey on Zoomerang
using a URL provided in the cover letter. All surveys returned
by October 31, 2005 were included in the study. It was
anticipated that the response rate of the questionnaires would
be at least 30%. The sample size was chosen to detect
differences of at least 25% in the response patterns between
disease groups with 80% power to a two-sided significance
level of 5%.
Statistical Analysis
Categorical data were summarized as frequencies and
percentages. All quantitative data were summarized by me-
dians and ranges. Response patterns between disease/smok-
ing status groups were performed using a Mantel–Haenszel
test. Pairwise comparisons between disease or smoking status
groups were performed using a 2 test or Fisher’s exact test
whenever appropriate. Comparisons between disease or smok-
ing status groups of continuous outcomes were performed using
a nonparametric Wilcoxon rank-sum test. All statistical tests
were two sided, and p  0.05 was used to indicate statistical
significance. Statistical analyses were performed using SAS
version 6.12 software (SAS Institute, Cary, NC).
RESULTS
Physician Characteristics and Response Rates
A total of 672 of 1132 physicians (59.4%) returned
their surveys. Briefly, the median age of the physicians was
46 years old, with approximately 65% of the participants
being male. The physicians had been in practice a median of
15 years and saw, on average, 77 to 80 patients per week. The
physicians stated that they saw approximately seven breast
cancer patients and four lung cancer patients per year. There
were no significant differences in the evaluated characteris-
tics between the two groups. Table 1 shows the characteris-
tics of the physicians who participated in the study.
Referral Patterns
The survey was designed so that three of the questions
concerned the physician’s choice on whether to refer the
patient to a clinical oncologist. The first question posed a
scenario for a newly diagnosed female patient with stage IB
lung or breast cancer. Of the 672 physicians, 656 (97.6%)
stated that they would refer their patients to a clinical oncol-
ogist for possible further treatment after surgical intervention.
There was no difference between physicians who received
scenarios with breast cancer patients and those who received
scenarios with lung cancer patients (p  0.857).
Nevertheless, when the patients were found to have
metastatic disease, physicians were less likely to refer lung
cancer patients than breast cancer patients to oncologists for
possible further treatment (Figure 1). In this scenario, the
breast and lung cancer patients both were described as having
proven hepatic and lung metastasis, but otherwise they felt
well, had good performance status, and were able to perform
their daily activities. Only 308 of 318 physicians would refer
a lung cancer patient for further therapy, compared with 345
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of 345 physicians who said they would refer a breast cancer
patient (97% versus 100%, p  0.001). Later in the question-
naire, physicians were asked about referral practices in pa-
tients with metastatic disease who had poor performance
status. Again, more physicians stated they would refer breast
cancer patients, but not lung cancer patients, to medical
oncologists (34% versus 20%, p  0.001).
Two additional questions evaluated why physicians
refer patients with metastatic disease to oncologists. More
physicians stated that they would refer their advanced-stage
lung cancer patients solely for supportive or palliative care
compared with breast cancer patients, whom they would refer
for further treatment (9% versus 3%, p  0.0092). In addi-
tion, more physicians stated that the stage of disease affected
their choice to refer to an oncologist in breast cancer com-
pared with lung cancer (p  0.001). Nevertheless, when
asked directly at the end of the survey in a true/false
question, physicians did not state that the type of malig-
nancy (p  0.185), degree of the patient’s symptoms (p 
0.115), the patient’s desire for a referral (p  0.496), the
patient’s age (p  0.258), the presence of comorbid medical
conditions (p 0.38), or the distance to travel for the referral
(p  0.235) impacted their decisions to refer patients to
oncologists (Table 2).
Influence of Tobacco Use
A secondary endpoint of our study was to determine
whether patients’ tobacco use influenced the physicians’ care
decisions. We found no significant differences in response to
any of the questions in the clinical scenarios between any of
the smoking and nonsmoking groups. Physicians noted they
would refer similar percentages of smoking and nonsmoking
patients with malignancies to oncologists, both in the setting
of early-stage (98% versus 97%, p  0.31) and metastatic
disease (99% versus 98%, p  0.49). The physicians also
were asked directly about factors that would influence their
decisions to refer these patients; according to their responses
to this question, patients’ tobacco use did not significantly
influence their decisions (Table 2).
Benefit of Therapy
An additional aim of this study was to determine the
awareness among primary physicians of new therapeutic
options for lung cancer. The first part of the clinical scenario
dealt with newly diagnosed cancer patients with stage IB
disease. Fewer physicians knew that adjuvant therapy bene-
fited lung cancer patients compared with breast cancer pa-
tients (11% versus 24%, p  0.001) (Figure 2). Later in the
survey, the questions referred to patients with metastatic
cancer who were otherwise asymptomatic. Compared with
their knowledge of breast cancer treatment, fewer physicians
knew that the treatment of advanced-stage lung cancer had a
survival benefit (41% versus 31%, p  0.0145) (Figure 2).
Patient Follow-up
The length of follow-up also was evaluated in patients
with advanced-stage malignancies who were in severe pain.
Physicians were asked whether they would see these patients
in 1 to 2 weeks, 1 to 2 months, or refer them to hospice for
pain control. More physicians stated that they would continue
to observe their patients with breast cancer every 1 to 2 weeks
as opposed to their lung cancer patients (77% versus 70%,
p  0.0256) (Figure 3). In addition, there was no significant
difference between the number of breast cancer and lung
cancer patients with poor performance status and metastatic
disease who were referred to hospice for end-of-life care
(91% versus 87%, p  0.11).
FIGURE 1. Number of patients with advanced-stage breast
or lung cancer and with both good (2) and poor (2)
performance status who would be referred to a medical
oncologist.
TABLE 1. Participating Physician Characteristics
Physicians Answering
Breast Cancer
Questionnaire
Physicians Answering
Lung Cancer
Questionnaire
n (n  352) (n  320) p
Years of practice 644 15.82 14.93 0.163
Number of patients per week 665 77.30 80.00 0.195
Number of breast cancer patients per year 653 7.61 7.12 0.802
Number of lung cancer patients per year 652 4.12 3.58 0.055
Gender 664 0.512
Female (%) 37 35
Male (%) 63 65
Age (yr) 634 46.30 46.14 0.702
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Number of Patients in the Physicians’ Practice
The numbers of patients with breast cancer and with
lung cancer in the physicians’ practice during the previous 12
months were evaluated to determine whether the physicians’
experience treating the disease impacted their care decisions.
There was no statistical difference in referral patterns for
physicians who had more than or fewer than four patients
with breast or lung cancer in their practice during the previ-
ous year for early-stage disease (98% versus 97% respec-
tively, p  0.56), advanced-stage disease (98% versus 99%,
p  0.10), or for the management of symptoms (95% versus
93%, p  0.13).
Physician Age
The age of each participating physician also was ex-
amined as a possible reflection of a physician’s knowledge
about recent advances in treatments for lung cancer, with the
assumption that younger physicians might be more ac-
quainted with the recent literature. The median age of the
physicians was 47 years old. The physicians were grouped
into those above and below the mean, and their responses
regarding patient treatment and referral (both in the settings
of early-stage and advanced disease) and symptom-control
management were evaluated. The age of a physician did not
impact his or her referral practices for patients with early- or
advanced-stage disease (98% for younger versus 97% for
older physicians [p 0.43] and 99% for younger versus 98%
for older physicians [p 0.20], respectively) or their practice
of symptom management in these patients (76% for younger
versus 71% for older physicians, p  0.13).
Physician Gender
The gender of each participating physician was evalu-
ated to determine whether it influenced the physicians’ treat-
ment decisions. There was no statistical difference observed
in the referral patterns for male versus female physicians for
early-stage disease (98% versus 98% respectively, p  0.96),
advanced-stage disease (98% versus 99%, p  0.10), or for
the management of symptoms (96% versus 93%, p  0.06).
DISCUSSION
The surveyed physicians in this study clearly have
shown a preference toward more aggressive referral patterns
in patients with metastatic breast cancer than in patients with
metastatic lung cancer. In addition, when lung cancer patients
were referred to medical oncologists, it was more often for
palliative care and symptom management only. In contrast,
breast cancer patients often were referred for evaluation for
possible treatment options, regardless of whether they had
localized or advanced-stage disease.
FIGURE 2. Percentage of physicians who felt that the pa-
tients with both early-stage and metastatic disease would
have improved survival with chemotherapy.
FIGURE 3. Percentage of physicians who stated that they
would continue to observe their patients with uncontrolled
pain every 1 to 2 weeks.
TABLE 2. Factors Contributing to the Primary Care Physicians’ Decision to Refer their Patient to an Oncologist on the Basis
of Disease Type and Patient Smoking Status
Physicians
Answering
Breast Cancer
Questionnaire
Physicians
Answering
Lung Cancer
Questionnaire
Physicians
Answering
Nonsmoking
Questionnaire
Physicians
Answering
Smoking
Questionnaire
n (n  352) (n  320) p n (n  352) (n  320) p
Type of cancer 655 2.47 2.59 0.185 655 2.51 2.55 0.785
Degree of symptoms 654 2.99 3.16 0.115 649 3.09 3.06 0.812
Patient’s desire for referral 652 2.18 2.27 0.496 652 2.30 2.14 0.056
Patient’s age 652 3.24 3.37 0.258 652 3.28 3.33 0.740
Patient’s comorbid medical conditions 650 2.95 3.05 0.380 650 2.99 3.01 0.718
Distance patient has to travel for the referral 646 3.51 3.64 0.235 646 3.60 3.55 0.445
The following scale was used for quantification of the physicians’ decision: 1  extremely important in my decision making about referral; 2  very important; 3  somewhat
important; 4  not too important; 5  not at all important in my decision making about referral.
Journal of Thoracic Oncology • Volume 2, Number 8, August 2007 Approach to Non-small Cell Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung Cancer 725
It is important to know the expected survival for all
stages of the two diseases, to understand how effective therapy
may be in either case. Early-stage breast cancer (stage I or II)
has an excellent 5-year survival rate of approximately 76% to
98%, and it often can be cured with aggressive treatment.1
Nevertheless, although the 5-year survival rate is approxi-
mately 16% in untreated metastatic breast cancer,1 there has
been an improvement in the median survival from 18 months
to 26 months during the past 20 years, with the development
of newer chemotherapeutics.12
Improvements in survival also have been observed in
the treatment of lung cancer. Recent studies have clearly
demonstrated that adjuvant therapy for early-stage non-small
cell lung cancer (NSCLC) (IB, II, and IIIA) improves sur-
vival, underlining the importance of aggressive chemother-
apy after surgical intervention.8,13–15 The improvement in
survival from chemotherapy is not limited to patients with
early-stage NSCLC. Patients with advanced-stage NSCLC
also have seen improvements in survival during recent years,
with improvements in median 1-year survival from 10% un-
treated to 30% with doublet chemotherapy.9 In certain subpopu-
lations of NSCLC, the median survival of patients treated with
chemotherapy plus bevacizumab, a monoclonal antibody to
vascular endothelial growth factor, is more than 50%.16
It is unclear why primary care physicians in this study
reported that they were more likely to refer advanced breast
cancer patients than advanced lung cancer patients for treat-
ment. When asked directly, physicians denied that the type of
malignancy or the degree of a patient’s symptoms influenced
the decision to refer the patient. Nevertheless, when the
physicians responded to the case scenarios, it was observed
that the type of malignancy, stage of disease, and degree of
patient symptoms did indeed influence the physicians’ deci-
sions to refer their patients. Of note, physicians observing
breast cancer patients for severe pain were likely to see them
at more frequent intervals than were those observing lung
cancer patients. The reason for this discrepancy is unclear,
but it was not attributable to a larger number of lung cancer
patients being referred for hospice care, because there was
not a significant difference in the percentage of patients
referred to hospice between the groups.
One possibility may be an unconscious bias induced by
the stigma of lung cancer being a “self-induced” disease.
Nevertheless, physicians were as likely to refer stage IB
breast cancer patients for further therapy after surgery as they
were to refer stage IB lung cancer patients. In addition, the
cancer patients’ history of tobacco use did not seem to have
any influence on the physicians’ care decisions. This brings
into question the possibility that the differences observed in
this study are related to the stigma of a self-induced disease.
It is possible that some physicians taking the survey simply
failed to recognize the smoking status of the patient in their
questionnaire. It is also possible that the stigma is not asso-
ciated with tobacco use but, rather, with the actual disease
itself. Primary physicians may have felt that the poor prog-
nosis of lung cancer compared with breast cancer warranted
a less aggressive approach. In any event, this was an inter-
esting finding in the study, and it deserves to be tested further
in the future.
Another reason might be differences in the physicians’
knowledge base regarding the benefits of both adjuvant and
“salvage” therapy for NSCLC. As discussed above, the ad-
vances in the treatment of NSCLC in both early-stage and
metastatic disease have been relatively recent, and they might
not be widely known or accepted. This is important because
patients cannot benefit from advances in therapy if they are
evaluated by physicians who not are aware of these advances.
A previous study by Earle et al.17 has shown that patterns of
care, particularly in the delivery of chemotherapy, were
driven by whether the patient did or did not see an oncologist.
One possibility is that the lack of knowledge regarding
lung cancer treatment and prognosis might be secondary to a
lack of experience in the care of lung cancer patients. Nev-
ertheless, when physicians were grouped by whether they
saw many (more than four) or relatively few (no more than
four) lung and breast cancer patients during the previous 12
months, there was no significant difference in their referral
and treatment decisions. We also evaluated this possibility by
assessing the age of each physician, assuming that a younger
age might imply more knowledge of the recent advances in
lung cancer. Nevertheless, no difference related to the phy-
sicians’ ages was seen in the care of patients with either
malignancy. Regardless of the cause, improvements in phy-
sicians’ knowledge about advances in the treatment of
NSCLC would, presumably, change their referral patterns or
treatment decisions, thus resulting in improved outcomes.
An interesting note is that although the participating
physicians were relatively unaware of the benefits of chemo-
therapy for patients with early- and advanced-stage lung
cancer, the percentage of physicians who said that they knew
the benefits of chemotherapy for early- and advanced-stage
breast cancer (24% and 41%, respectively), although higher,
were also markedly low. The reason for this is unclear, but it
is likely related to many of the same factors that have been
described above (i.e., knowledge about advancements in
therapy, number of breast cancer patients seen, etc.). It would
be interesting to further evaluate this finding in a study
targeted towards physicians treating breast cancer patients.
Some limitations of the study must be acknowledged.
First, because the group of physicians surveyed in this study
was a convenience sample taken from a single state, they
might not be representative of primary care physicians through-
out the country; this might limit generalization of the results.
Second, there may be a nonresponse bias, because approxi-
mately 41% of the physicians asked to participate in the study
did not return their surveys, and their responses may have
differed from those of our participant population. A third
limitation, inherent to survey studies, is that sources of error
can result from the wording of the survey questions, which
may cause participants to interpret the same question differ-
ently.18 Fourth, the study was designed to detect only abso-
lute differences of 25% or greater between groups; thus,
small but potentially significant differences regarding all of
the above factors might have been missed. Finally, it is
important to again point out that we measured physicians’
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self-reports of their practice and not of their actual practice
patterns, which may be different.
Regardless of these possible limitations, this study dem-
onstrates a difference in referral patterns between advanced
breast cancer and lung cancer patients, and this difference might
be attributable to many potential factors, such as a knowledge
gap regarding advancements in cancer therapy, or, possibly, the
existence of a subconscious bias against lung cancer patients.
Thus, it will be important to identify the potential factors
involved to ensure that lung cancer patients are benefiting from
recent advances in chemotherapy. Specific studies designed to
educate primary physicians on the recent improvements in the
therapies for NSCLC, both in early- and advanced-stage disease,
are needed to determine whether improved knowledge would
lead to a change in their referral patterns and, ultimately, to
improvements in overall patient survival.
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